Cadila Healthcare's formulation manufacturing plant gets USFDA approval

25 Jul 2011 Evaluate

Zydus group - Cadila Healthcare’s formulation manufacturing plant at Baddi, Himachal Pradesh has been approved by USFDA. With the approval in place the plant which currently caters to the domestic and emerging market requirements will commence supplies to the US market.

The USFDA approval for the Baddi plant enabled the company to open up an additional resource to cater to the growing needs of its US business. The ultra modern Baddi plant was commissioned in 2007 and manufactures oral solid dosage forms which include hard gelatin capsules and tablets.

Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

1060.90 -15.00 (-1.39%)
27-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1466.70
Dr. Reddys Lab 5875.90
Cipla 1478.35
Zydus Lifesciences 1060.90
Lupin 1615.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.